Mikhail Blagosklonny is a scientist and a doctor of oncology. He received an MD (Doctor of Medicine) specializing in internal medicine and a PhD in heart studies and experimental medicine from the First Pavlov State Medical University of St. Petersburg. Mikhail Blagosklonny is currently an oncology professor at Roswell Park Cancer Institute in New York.
His education and employment background has given him a vast knowledge for research in the fields of cancer and the associated therapies that protect normal cells from being damaged during treatment. He also has research interests in the areas of anti-aging medications and the underlying mechanisms of aging. Blagosklonny has developed a hypothesis about the role of TOR (target of rapamycin) in the aging process and cancer treatment. Rapamycin is a drug used for cancer treatment that is also effective in the anti-aging process. Dr. Blagosklonny is very passionate and an advocate for rapamycin in longevity research and more informatoin click here.
Through his studies and research, Blagosklonny has found that correct dose of rapamycin will result in the extension of a particular lifespan. He found the process is the same in any age group, although younger users may experience much different side effects than those in the older groups. He also advises gerontologists to switch studies from random molecular damage accumulation to post aging syndrome. The findings from the change in the approach will allow doctors and other research professionals to study more effectively those who reach post aging age categories. The drug has been shown to slow the aging process and extends the lifespan beyond the normal predicted age group. Blagosklonny is considered a pioneer in the field of anti-aging and longevity and what Mikhail knows.
Dr. Blagosklonny has also taken on editor-in-chief of publications such as Oncotarget, Aging and Cell Cycle. He is also the editor of Cancer Biology & Therapy and an editorial board member of Cell Death & Differentation. The Doctor has also authored more than 270 papers in peer-reviewed journals with more than 25,000 citations. His work is highly regarded and often used as the basis for research in new avenues. He recognizes that journals and research publications are an important medium to keep others informed about the advances in science, medicine and research and a way to share ideas and Mikhail’s lacrosse camp.
Previous employment opportunities include senior scientist at Ordway Research Institute in Albany, New York, associate professor of medicine at New York Medical College in Valhalla, New York. In 2009, Blagosklonny was appointed professor of Oncology at Roswell Park Cancer Institute.